TY - JOUR
T1 - Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors
AU - Klomp, I.
AU - Dalm, S. U.
AU - van Koetsveld, P. M.
AU - Dogan-Oruc, F.
AU - de Jong, M.
AU - Hofland, L. J.
PY - 2020/9
Y1 - 2020/9
N2 - Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.
AB - Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000577424101028&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s00259-020-04988-4
DO - 10.1007/s00259-020-04988-4
M3 - Meeting Abstract
SN - 1619-7070
VL - 47
SP - S411-S412
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - Suppl 1
M1 - OP-830
T2 - 33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)
Y2 - 22 October 2020 through 30 October 2020
ER -